LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Kodu・Aktsiate loetelu・Ovid therapeutics Inc

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.57 -5.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.54

Max

2.7199999999999998

Põhinäitajad
By Trading Economics
Sissetulek	-27M -17M
Aktsiakasum	-0.125
Kasumimarginaal	-2,366.017
Töötajad	23
EBITDA	-5.5M -18M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+95.24% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-19M 464M
Eelmine avamishind	8.08
Eelmine sulgemishind	2.57

Uudiste sentiment

By Acuity

50%

124 / 344 Pingereas Healthcare

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. mai 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31. mai 2026, 22:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29. mai 2026, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29. mai 2026, 23:06 UTC

Omandamised, ülevõtmised, äriostud

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29. mai 2026, 20:53 UTC

Tulu

Oil Declines Lift Stocks to Fresh Records -- WSJ

29. mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29. mai 2026, 20:11 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 19:47 UTC

Tulu

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29. mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29. mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29. mai 2026, 19:05 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29. mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29. mai 2026, 18:12 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29. mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29. mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29. mai 2026, 17:55 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29. mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29. mai 2026, 17:00 UTC

Tulu

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29. mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29. mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29. mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

95.24% tõus

12 kuu keskmine prognoos

Keskmine 5.33 USD 95.24%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

124 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.